TY - JOUR
T1 - Delivery of biologics in cardiovascular regenerative medicine
AU - Bartunek, J.
AU - Sherman, W.
AU - Vanderheyden, M.
AU - Fernandez-Aviles, F.
AU - Wijns, W.
AU - Terzic, A.
PY - 2009/5
Y1 - 2009/5
N2 - Stem cell-based cardiovascular regenerative medicine offers the next frontier of therapy through delivery of progenitor cells to achieve structural and functional repair of the myocardium. Initial clinical experience indicates that such therapy is feasible and safe, yet structural and functional benefits remain rather modest. A common pitfall in all studies is the very low rate of cell retention by the recipient myocardial tissue. This limitation warrants lead optimization so as to improve the outcome of stem cell delivery.
AB - Stem cell-based cardiovascular regenerative medicine offers the next frontier of therapy through delivery of progenitor cells to achieve structural and functional repair of the myocardium. Initial clinical experience indicates that such therapy is feasible and safe, yet structural and functional benefits remain rather modest. A common pitfall in all studies is the very low rate of cell retention by the recipient myocardial tissue. This limitation warrants lead optimization so as to improve the outcome of stem cell delivery.
UR - http://www.scopus.com/inward/record.url?scp=67349247807&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=67349247807&partnerID=8YFLogxK
U2 - 10.1038/clpt.2008.295
DO - 10.1038/clpt.2008.295
M3 - Article
C2 - 19212313
AN - SCOPUS:67349247807
SN - 0009-9236
VL - 85
SP - 548
EP - 552
JO - Clinical pharmacology and therapeutics
JF - Clinical pharmacology and therapeutics
IS - 5
ER -